A three-dose recombinant vaccine (Hecolin®) against hepatitis E has been licensed in China since 2011. We caught up with Dr Iza Ciglenecki (Médecins Sans Frontières, Geneva, Switzerland) to discuss the prognosis and treatment paradigm for hepatitis E, the challenges associated with optimizing hepatitis E vaccine efficacy and reducing the burden of disease, and what is known about the efficacy of the Hecolin® vaccine in the prevention of hepatitis E.
The abstract ‘The first mass reactive vaccination campaign against hepatitis E in Bentiu, South Sudan: feasibility, vaccination coverage and two-dose vaccine effectiveness‘ was presented at EASL 2023, 21–24 June 2023, Vienna, Austria.
Questions:
- What is the prognosis and treatment paradigm for hepatitis E? (0:20)
- What are the challenges associated with optimizing hepatitis E vaccine efficacy and reducing the burden of disease? (1:01)
- What is already known about the efficacy of the Hecolin® vaccine in the prevention of hepatitis E? (2:03)
Disclosures: Iza Ciglenecki has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry.
Filmed in coverage of EASL 2023
Access further content on hepatitis
